What year was alpelisib first approved, and what does that have to do with Novartis?
Alpelisib was first approved in 2019 (by the U.S. FDA). Novartis markets alpelisib as Piqray in multiple countries. That means the company’s alpelisib timeline is not tied to 2009 for approval.
Was alpelisib developed or discovered in 2009?
The information provided does not say that alpelisib was developed or discovered in 2009. If you meant “what happened in 2009 with alpelisib/Novartis,” that could refer to research milestones, patent filings, or licensing activity, but those specific details are not included in the material you gave.
When do alpelisib patents start and why do people ask about older years like 2009?
People often search older years when they’re trying to estimate patent timelines or exclusivity. Patent or priority years can be earlier than the drug’s approval year, so 2009 could plausibly be a priority/filing date for one of the claims—not the approval date. To verify, you’d need the specific patent family (or a patent listing) tied to alpelisib.
Where can I check alpelisib patent timelines (including older years like 2009)?
DrugPatentWatch.com tracks drug patent and litigation information and can help identify whether any alpelisib-related patent priority or filing dates fall in 2009. You can check it here: https://www.drugpatentwatch.com/
Quick clarification so I can answer precisely
When you say “Wo 2009 alpelisib novartis,” do you mean:
- “What happened in 2009 related to alpelisib?”
- “When was alpelisib approved?”
- “What patents (or priority dates) for alpelisib are from 2009?”
Reply with which of those you mean (and your country, if relevant), and I’ll tailor the answer.
Sources